Hepatitis C News and Research

Latest Hepatitis C News and Research

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant to Aeras in support of a collaboration among the three parties to support the development of vaccines against tuberculosis, HIV and malaria.

7 May 2013

Health providers with hepatitis B are covered by disability law

The U.S. Department of Justice recently declared in a legal settlement that hepatitis B patients are protected by federal disability law.

7 May 2013

First Edition: May 6, 2013

Kaiser Health News staff writer Phil Galewitz, working in collaboration with The Washington Post, reports: "Florida is on course to spend $6 million to reach out to nearly 4 million uninsured people and help them sign up for coverage in the federal health law's online marketplace this fall.

6 May 2013

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.

4 May 2013

New screening guidelines: An important shift in HIV testing

Beth Meyerson, health policy expert at the Indiana University School of Public Health-Bloomington, said the new screening guidelines by the U.S. Preventive Services Task Force represent an important shift in HIV testing and will result in more HIV screenings because they will now be reimbursable. But the availability of the tests remains a big unknown.

2 May 2013

HCV screening of prison inmate drug users: an interview with Dr. Arthur Kim, Massachusetts General Hospital and Harvard Medical School

Prisoners overall have a very high rate of past or present injection drug use, which is a major risk factor for HCV infection due to repeated exposures to needles.

1 May 2013

Schizophrenia cardiovascular risk under-recognized in primary care

UK researchers have found that despite being a major contributor to premature deaths among patients with schizophrenia, cardiovascular disease is less likely to be recorded on their primary care records than those of people without schizophrenia.

30 Apr 2013

Somalia launches pentavalent vaccine with support from GAVI, UNICEF, WHO

"Coinciding with World Immunization Week, the Somali government announced on 24 April its intention to vaccinate all children under the age of one with a new five-in-one vaccine, known as a pentavalent vaccine, funded by the GAVI Alliance, with [UNICEF] and the [WHO] as implementing partners," IRIN reports.

30 Apr 2013

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus.

29 Apr 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.

29 Apr 2013

Baby boomers need to get tested for hepatitis C

If you were born during 1945-1965, talk to your doctor about getting tested for hepatitis C. Baby boomers are five times more likely than other adults to be infected. In fact, 75 percent of adults with hepatitis C were born during these years.

29 Apr 2013

UK’s health performance: an interview with Prof. Murray, University of Washington

Rates of premature mortality in the UK have been falling steadily, but the pace of decline is not as fast as in many other high-income countries, such as Australia. In that sense, the UK lags behind.

29 Apr 2013

GS-9620 therapy suppresses hepatitis B virus infection

A novel drug developed by Gilead Sciences and tested in an animal model at the Texas Biomedical Research Institute in San Antonio suppresses hepatitis B virus infection by stimulating the immune system and inducing loss of infected cells.

29 Apr 2013

Calcipotriol drug offers a potential treatment option for fibrotic diseases

Liver fibrosis results from an excessive accumulation of tough, fibrous scar tissue and occurs in most types of chronic liver diseases. In industrialized countries, the main causes of liver injury leading to fibrosis include chronic hepatitis virus infection, excess alcohol consumption and, increasingly, nonalcoholic steatohepatitis (NASH).

26 Apr 2013

NAFLD is an independent predictor of cardiovascular risk

A study presented today at the International Liver CongressTM 2013 - which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) - showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.

26 Apr 2013

Urine tests could improve diagnosis of liver cancer

New data from two clinical trials presented today at the International Liver Congress- 2013 demonstrate substantial improvements in the detection of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) using diagnostic urine tests.

26 Apr 2013

New hope for patients with chronic HBV infection

Exciting new data presented today at the International Liver Congress- 2013 include rults from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for chronic hepatitis B virus (HBV) infection.

25 Apr 2013

Studies demonstrate encouraging results for new direct-acting antiviral agents

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2013 demonstrate encouraging results in the use of new direct-acting antiviral agents (DAAs) for the treatment of hepatitis C.

25 Apr 2013

Schizophrenia cardiovascular risk under-recognized in primary care

25 Apr 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Health providers with hepatitis B are covered by disability law

First Edition: May 6, 2013

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

New screening guidelines: An important shift in HIV testing

HCV screening of prison inmate drug users: an interview with Dr. Arthur Kim, Massachusetts General Hospital and Harvard Medical School

Schizophrenia cardiovascular risk under-recognized in primary care

Somalia launches pentavalent vaccine with support from GAVI, UNICEF, WHO

BioLineRx starts enrollment in Phase I/II trial of BL-8020 for treatment of HCV

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Baby boomers need to get tested for hepatitis C

UK’s health performance: an interview with Prof. Murray, University of Washington

GS-9620 therapy suppresses hepatitis B virus infection

Calcipotriol drug offers a potential treatment option for fibrotic diseases

NAFLD is an independent predictor of cardiovascular risk

Urine tests could improve diagnosis of liver cancer

New hope for patients with chronic HBV infection

Studies demonstrate encouraging results for new direct-acting antiviral agents

Schizophrenia cardiovascular risk under-recognized in primary care

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in